Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
Key Highlights
- ➤ZORYVE Q3 net product revenue $143.9 million, up 45% year over year
- ➤2026 net product sales guidance raised to $535 million–$545 million
- ➤Q3 net income $8.8 million, versus $7.4 million in Q3 2025
- ➤FDA target action date set for February 23, 2027, for infant atopic dermatitis indication
- ➤ARQ-234 Phase 1 trial advanced to multiple ascending dose portion
Expert Statements
Frank Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics
“Yet another strong quarter of performance reflects the consistent execution of our corporate strategy and further strengthens our financial position. ZORYVE continues to lead the branded non-steroidal topical segment driven by its efficacy and tolerability across multiple inflammatory skin conditions and patient populations. We are very excited to launch a new awareness campaign with Simone Biles, a World Champion gymnast who uses ZORYVE herself, to raise awareness of inflammatory skin diseases and of advanced targeted topicals like ZORYVE”
Frank Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics
“Looking ahead, with a potential FDA approval of ZORYVE cream 0.05% for infants as young as 3 months in the first quarter of 2027, the progress of our indication expansion trials, and the advancement of our ARQ-234 Phase 1 trial, we are well positioned to drive continued growth.”
* Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q3 revenues of $143.9 million, +45% versus Q3 of 2025, and +11% versus Q2 of 2026, driven by strong demand growth * Raised 2026 full-year net product sales guidance to $535 million–$545 million * Partnered with World Champion gymnast Simone Biles to launch the Skin to Believe In awareness campaign for individuals living with inflammatory skin conditions * Remains on track to disclose topline results from Phase 2 trial of ZORYVE foam 0.3% in individuals with vitiligo and decision on program advancement in Q4 of 2026 * Maintained positive operating cash flow for the quarter with $18.9 million of net cash provided by operating activities WESTLAKE VILLAGE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter ended September 30, 2026, and provided a business update.
Get started
Create a free account to read the full story.